Latuda is a medicine that is used to treat patients from 13 years of age with schizophrenia, a mental illness with symptoms that include disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Latuda contains the active substance lurasidone.
Latuda : EPAR - Medicine overview (PDF/128.82 KB)
First published: 08/04/2014
Last updated: 14/09/2020
Latuda : EPAR - Risk-management-plan summary (PDF/265.98 KB)
First published: 13/05/2014
Last updated: 12/12/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Aziende Chimiche Riunite Angelini Francesco S.p.A.
|Date of issue of marketing authorisation valid throughout the European Union||
25/08/2020 Latuda - EMEA/H/C/002713 - II/0029
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Treatment of schizophrenia in adults aged 18 years and over.